**Specifications Table**TableSubject area*Biology*More specific subject area*Vascular physiology*Type of data*Tables and Figures*How data was acquired*Flow-mediated vasodilation test using ultrasonic diagnostic equipment*Data format*Raw, Analyzed*Experimental factors*The brachial artery was monitored using ultrasonic diagnostic equipment, and the diameter was calculated. In addition, blood pressure was assessed.*Experimental features*A cross-over design was utilized. The camu camu extract/placebo was administered under conditions of dietary restrictions to avoid confounding.*Data source location*Abashiri, Japan*Data accessibility*The data are supplied with this article.*

**Value of the data**•The data provide insights into the effect of camu camu pericarp extract on blood flow-mediated vasodilation and blood pressure.•The data can be used as a reference for comparisons with other foods that affect flow-mediated vasodilation and blood pressure.•The data describe a valuable and searchable functional food resource and can be used for future functional food studies.

1. Data {#s0005}
=======

Flow-mediated vasodilation (FMD), which is the dilation response of the artery to the shear stress of blood flow, can be represented by the changes in brachial arterial diameter after an increase in blood flow. In clinical medicine and functional food studies, FMD measurements serve as a noninvasive method to study endothelial function [@bib1], [@bib2], [@bib3]. The changes in arterial diameter after the administration of camu camu pericarp extract or a placebo are shown in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}. The arterial diameter values that were used to generate the line graphs in [Fig. 1](#f0005){ref-type="fig"} are presented in [Table 1](#t0005){ref-type="table"}. The blood pressure data recorded are shown in [Table 2](#t0010){ref-type="table"}.Fig. 1Arterial diameter changes by the FMD response in the male participants administered either the camu camu pericarp extract or placebo.Fig. 1Fig. 2Arterial diameter changes by the FMD response in the female participants administered either the camu camu pericarp extract or placebo.Fig. 2Table 1Arterial diameter (mm) changes by the FMD response in the participants administered either the camu camu pericarp extract or placebo.Table 1Time (s)2030405060708090100110MaleAPlacebo3.773.964.014.044.013.993.953.913.883.91Camu camu3.843.944.054.074.134.054.013.883.873.89BPlacebo3.873.903.974.004.013.933.873.863.803.74Camu camu3.323.393.463.533.673.703.603.613.483.46CPlacebo4.144.224.304.364.374.354.294.284.244.17Camu camu3.813.924.003.994.043.993.943.873.833.82DPlacebo3.213.293.393.433.433.473.453.343.323.27Camu camu3.113.273.273.363.333.343.343.213.183.19EPlacebo3.924.024.114.164.214.204.194.174.154.11Camu camu3.924.004.184.184.354.104.063.993.973.88FPlacebo3.263.273.323.383.333.453.393.333.243.14Camu camu3.293.473.603.653.513.503.413.333.243.28GPlacebo3.363.403.493.603.673.633.583.533.553.54Camu camu3.583.593.743.763.793.703.733.673.693.64HPlacebo4.124.264.364.294.224.274.284.234.164.15Camu camu3.854.034.104.234.244.133.963.923.943.88IPlacebo3.493.563.623.613.673.613.593.563.493.46Camu camu3.203.273.413.413.453.513.373.383.323.29JPlacebo3.183.393.603.723.643.593.563.503.453.44Camu camu3.493.583.653.693.613.493.403.383.343.39FemaleAPlacebo3.033.153.233.303.323.253.183.163.123.12Camu camu2.933.073.233.253.393.253.173.153.023.01BPlacebo3.293.333.333.443.323.313.213.183.213.17Camu camu2.822.852.902.952.902.932.872.772.752.69CPlacebo3.333.433.533.553.603.503.453.363.343.33Camu camu3.253.293.333.363.363.373.353.363.283.18DPlacebo3.994.114.194.234.174.114.053.973.903.87Camu camu2.883.033.083.113.193.243.213.113.073.00EPlacebo2.732.812.772.742.652.702.682.662.652.60Camu camu2.722.892.892.963.103.092.982.902.922.82FPlacebo2.772.852.932.913.102.982.942.962.922.88Camu camu2.682.892.973.013.033.052.972.902.772.73GPlacebo3.223.453.523.553.503.483.463.423.363.33Camu camu3.063.303.433.463.503.433.413.373.263.27HPlacebo3.573.883.893.873.813.843.773.793.763.74Camu camu3.713.813.873.893.873.873.823.783.753.67IPlacebo2.432.472.512.652.662.712.692.632.632.57Camu camu2.532.732.782.822.912.932.912.892.832.75JPlacebo2.742.782.832.882.902.922.902.912.872.82Camu camu2.632.712.852.882.922.932.912.852.872.80Table 2Blood pressure measurements of the participants administered either the camu camu extract or placebo.Table 2Blood pressure (mmHg)SystolicDiastolicParticipantPlaceboCamu camuPlaceboCamu camuMaleA1361334655B1281096664C1101035359D116996969E1181056855F1181176865G1071036160H1131118573I1021076767J1101117574FemaleA92975658B89876054C931085568D1161026964E61805546F107947055G96805447H94955761I90995755J98986068

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Participants {#s0015}
-----------------

Twenty healthy students (10 men and 10 women; age range, 18--28 years) from the Hokkaido Okhotsk Campus of the Tokyo University of Agriculture were recruited in July 2017. Individuals with a history of hypertension, diabetes mellitus, or dyslipidemia were excluded because of the potential effects of these conditions on endothelial function. The study protocol was approved by the Tokyo University of Agriculture Committee of Human Subject Research Ethics. Informed consent was obtained from all participants.

2.2. Materials {#s0020}
--------------

The extract was prepared by stirring dried camu camu pericarps (1.5 kg) in two-fold volume of 50% ethanol for 2 h. The solution was filtered using filter paper, and the filtrate was collected. The filtered residue was subjected to a second round of ethanol extraction with same volume of 50% ethanol. The filtrates from the first and second rounds of ethanol extraction were pooled, and the ethanol was removed by evaporation; the filtrate was then freeze-dried. The freeze-dried powder was encapsulated into soft gelatin capsules (25 mg in each capsule) (Matsuya, Osaka, Japan). Three capsules containing the camu camu extract comprised a single dose; whereas, three soft capsules containing 25 mg of water each were administered as the placebo. The food restriction protocol involved the use of cereal (Flugra, Calbee, Tokyo, Japan) for meals.

2.3. Food restriction protocol and FMD measurement {#s0025}
--------------------------------------------------

The data were collected at the Hokkaido Okhotsk Campus of the Tokyo University of Agriculture between August and September 2017. By applying a cross-over design, each participant was randomly administered a single dose of the camu camu pericarp extract or water (placebo) in a soft capsule. The second dose was administered more than a week later. The food restriction protocol and FMD were assessed using ultrasonic diagnostic equipment (LOGIQ P6, GE Healthcare, Little Chalfont, UK), as previously reported [@bib1]. Arterial diameter was calculated using the FMDscope software (Media Cross Co. Ltd, Japan). Blood pressure was measured using an electronic sphygmomanometer (ES-P2000, Terumo, Tokyo, Japan).
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